KFDA approves zoledronic acid

Novartis Korea announced that it has recently received marketing authorization from the Korea Food and Drug Administration for Zometa (zoledronic acid), a highly potent intravenous bisphosphonate, for the treatment of musculoskeletal disorders or bone complications associated with bone metastatis in patients with advance prostate cancer.

Korea has few drugs effective for the treatment of bon...